Cargando…

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?

BCL-2 family proteins regulate the intrinsic pathway of programmed cell death (apoptosis) and play a key role in the development and health of multicellular organisms. The dynamics of these proteins' expression and interactions determine the survival of all cells in an organism, whether the hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leverson, Joel D., Cojocari, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204401/ https://www.ncbi.nlm.nih.gov/pubmed/30406027 http://dx.doi.org/10.3389/fonc.2018.00458

Ejemplares similares

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

Mechanisms of venetoclax resistance and solutions
por: Liu, Jiachen, et al.
Publicado: (2022)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
por: Li, Qingfang, et al.
Publicado: (2019)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
por: Yuan, Delin, et al.
Publicado: (2021)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
por: Guarente, Valerio, et al.
Publicado: (2021)

Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
por: Leverson, Joel D.
Publicado: (2015)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor
por: Wei, Zhuang, et al.
Publicado: (2021)

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
por: Sarapura Martinez, Valeria J., et al.
Publicado: (2023)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
por: Ballotta, Laura, et al.
Publicado: (2021)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
por: Birkinshaw, Richard W., et al.
Publicado: (2019)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
por: Chong, Stephen Jun Fei, et al.
Publicado: (2023)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
por: Salah, Haneen T., et al.
Publicado: (2021)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma
por: Liu, Meng-Ke, et al.
Publicado: (2022)

Editorial: Tumor Microenvironment and Resistance to Current Therapies
por: Lasfar, Ahmed, et al.
Publicado: (2019)

Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapies
por: Decock, Julie, et al.
Publicado: (2023)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
por: Garg, Ravendra, et al.
Publicado: (2020)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
por: Fiorcari, Stefania, et al.
Publicado: (2022)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2021)

Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer
por: Yang, Mengxuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1vs869dq09cosi2h3e89fkqabe